Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Recruiting 1Active not recruiting 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Head & Neck 9Thoracic 3Gastrointestinal 3Other solid neoplasm 2Gynecologic 2Sarcoma 1NET 1Genitourinary 1Endocrine 1Dermatologic 1Breast 1

Conditions

Mesothelioma 21Mesothelioma, Malignant 18Advanced Solid Tumor 17Carcinoma, Non-Small-Cell Lung 15Solid Tumor 14Advanced Solid Tumors 13Melanoma 12Esophageal Neoplasms 10Carcinoma, Renal Cell 10Stomach Neoplasms 9Squamous Cell Carcinoma of Head and Neck 9Uterine Cervical Neoplasms 8Solid Tumors 8Ovarian Neoplasms 8Solid Tumor, Adult 7Neoplasm Metastasis 7Colorectal Neoplasms 7Triple Negative Breast Neoplasms 6Small Cell Lung Carcinoma 6Breast Neoplasms 6Pancreatic Neoplasms 5Lung Neoplasms 5Endometrial Neoplasms 5Cholangiocarcinoma 5Neoplasms 4Locally Advanced or Metastatic Solid Tumors 4Head and Neck Neoplasms 4Advanced or Metastatic Solid Tumors 4Urinary Bladder Neoplasms 3Solid Tumor Malignancies 3

Interventions

pembrolizumab 2SS1(dsFv)PE38 2entinostat 1Tablets 1Quality of Life 1Polymerase Chain Reaction 1Patient Reported Outcome Measures 1Molecular Diagnostic Techniques 1Microarray Analysis 1Immunotherapy 1Immunoenzyme Techniques 1Gene Expression Profiling 1Flow Cytometry 1Fentanyl 1Erlotinib Hydrochloride 1Drug Therapy 1Combined Modality Therapy 1Biological Therapy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Salivary Gland Neoplasms × pembrolizumab × Other solid neoplasm × Clear all
NCT03556228 2025-12-11

VMD-928 Monotherapy and in Combination With Pembrolizumab to Treat TrkA Overexpression Driven Solid Tumors or Lymphoma

VM Oncology, LLC

Phase 1/2 Recruiting
242 enrolled
GastrointestinalHead & NeckOther solid neoplasmThoracic

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Carcinoma, Adenoid Cystic, Esophageal Neoplasms, Head and Neck Neoplasms, Laryngeal Diseases, Lung Neoplasms, Mesothelioma, Neoplasm Metastasis, Pancreatic Neoplasms, Salivary Gland Neoplasms, Tracheal Diseases, Small Cell Lung Carcinoma

NCT02628067 2025-09-22

KEYNOTE 158

Merck Sharp & Dohme LLC

Phase 2 Active not recruiting
1,609 enrolled 4 FDA
EndocrineGastrointestinalGynecologicHead & NeckNETOther solid neoplasmThoracic

Parkinson Disease 4, Autosomal Dominant Lewy Body, Anus Neoplasms, Bile Duct Neoplasms, Biliary Tract Neoplasms, Carcinoid Tumor, Uterine Cervical Neoplasms, Mesothelioma, Parotid Neoplasms, Salivary Gland Neoplasms, Thyroid Neoplasms, Vulvar Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms, Cholangiocarcinoma, Neuroendocrine Tumors, Microsatellite Instability, Small Cell Lung Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡